002603.SZ
以岭药业
SZSE · Healthcare · C 制造业 · CN
CNY 15.84
−3.71%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.9B | 7.8B | 6.5B | 10.3B | 12.5B |
| Cost of Revenue | 2.7B | 2.8B | 3.2B | 4.4B | 4.5B |
| Gross Profit | 5.2B | 5.0B | 3.3B | 5.9B | 8.0B |
| Operating Expenses | |||||
| R&D Expense | 728.0M | 718.3M | 826.6M | 853.2M | 1.0B |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 534.2M | 535.0M | 600.0M | 592.0M | 612.2M |
| Selling & Marketing Expense | 2.0B | 2.0B | 2.3B | 2.7B | 3.3B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 3.5B | 3.4B | 3.9B | 4.3B | 5.1B |
| Cost and Expenses | 6.1B | 6.1B | 7.1B | 8.7B | 9.7B |
| Operating Income (EBIT) | 1.7B | 1.6B | (688.9M) | 1.8B | 2.8B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.7B | 1.6B | (800.2M) | 1.7B | 2.8B |
| Income Tax Expense | 320.4M | 309.9M | (66.0M) | 339.9M | 422.9M |
| Bottom Line | |||||
| Net Income | 1.4B | 1.3B | (724.5M) | 1.4B | 2.4B |
| Earnings from Cont. Ops | 1.4B | 1.3B | (734.2M) | 1.3B | 2.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.4B | 1.3B | (724.5M) | 1.4B | 2.4B |
| Per Share | |||||
| Basic EPS | CN¥0.82 | CN¥0.77 | (CN¥0.43) | CN¥0.81 | CN¥1.41 |
| Diluted EPS | CN¥0.82 | CN¥0.77 | (CN¥0.43) | CN¥0.81 | CN¥1.41 |
| Revenue Per Share | CN¥4.74 | CN¥4.69 | CN¥3.90 | CN¥6.18 | CN¥7.50 |
| Shares | |||||
| Basic Shares Outstanding | 1.7B | 1.7B | 1.7B | 1.7B | 1.7B |
| Diluted Shares Outstanding | 1.7B | 1.7B | 1.7B | 1.7B | 1.7B |
| Profitability Metrics | |||||
| EBITDA | — | 2.2B | (84.9M) | 2.3B | 3.3B |
| D&A | — | 619.8M | 603.9M | 541.6M | 441.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026